Table 4

Relationship Between IPST and Subsequent 48-Hour and 30-Day Adverse Ischemic Events

Time Point/
Endpoint
IPST
(n = 89)
No IPST
(n = 10,850)
UnadjustedAdjusted
OR (95% CI)p ValueAOR (95% CI)p Value
48 h
 Death/MI/IDR/ARC-ST26 (29.2)490 (4.5)8.73 (5.48–13.90)<0.000111.85 (7.08–19.84)<0.0001
 Death5 (5.6)31 (0.3)20.77 (7.89–54.73)<0.000120.82 (7.34–59.02)<0.0001
 ARC definite ST3 (3.4)31 (0.3)12.17 (3.65–40.58)<0.000112.15 (3.46–42.68)<0.0001
 IDR4 (4.5)62 (0.6)8.19 (2.91–23.01)<0.000110.32 (3.50–30.37)<0.0001
 MI23 (25.8)439 (4.0)8.26 (5.09–13.41)<0.000112.00 (6.97–20.64)<0.0001
30 days
 Death/MI/IDR/ARC-ST28 (31.5)617 (5.7)7.60 (4.82–11.97)<0.00019.65 (5.86–15.89)<0.0001
 Death9 (10.1)106 (1.0)11.38 (5.57–23.27)<0.000112.25 (5.76–26.05)<0.0001
 ARC ST5 (5.6)86 (0.8)7.44 (2.95–18.79)<0.00017.56 (2.91–19.65)<0.0001
 ARC definite ST4 (4.5)61 (0.6)8.31 (2.95–23.36)<0.00018.17 (2.81–23.77)<0.0001
 IDR5 (5.6)117 (1.1)5.45 (2.17–13.68)<0.00016.36 (2.46–16.40)<0.0001
 MI24 (27.0)473 (4.4)8.08 (5.02–13.03)<0.000111.34 (6.66–19.30)<0.0001

Values are n (%).

AOR = adjusted odds ratio; ARC = Academic Research Consortium; IDR = ischemia-driven revascularization; OR = odd ratio; ST = stent thrombosis; other abbreviations as in Tables 1 and 2.

  • 30-day efficacy data were unavailable in 20 patients in the no-IPST group (n = 10,830). Propensity score based upon age, sex, smoking status, U.S. versus non-US region, race, weight, biomarker, previous MI (stable angina vs. NSTE-ACS vs. STEMI), previous PCI, previous CABG, peripheral artery disease, patient presentation, worst pre-procedure TIMI score, stent type, bifurcation treatment, aspirin dose, number of treated vessels, clopidogrel loading received, clopidogrel loading dose (300 vs. 600 mg), cangrelor infusion duration, bivalirudin received. Missing data were excluded from the modeling.